Zydus and MSN Launched Generic Adempas in U.S.

The companies introduced generic riociguat to provide a lower-cost treatment for rare lung conditions.

Updated on Oct. 5, 2026 in Healthcare

Isometric editorial illustration of uniform glass medicine vials arranged on a sterile surface, representing a pharmaceutical product launch. — Zydus Lifesciences and MSN Laboratories have introduced the first generic versions of the pulmonary hypertension medication Adempas to the U.S. market. AI Illustration. Upload story photo >

Live Poll

Do you believe the introduction of generic drug versions effectively reduces your long-term healthcare costs?

Zydus Lifesciences and MSN Laboratories have launched the first generic versions of Adempas in the United States. The FDA-approved medication treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Why it matters

This launch introduces a more affordable alternative for patients requiring long-term treatment for these rare lung diseases. The product release follows global sales for the brand-name drug reaching approximately $850 million in 2025.

The generic riociguat is now available in five dosage strengths ranging from 0.5 mg to 2.5 mg. Zydus Lifesciences shares on the NSE closed at ₹1,139, representing a 0.58% decline.

The players

Zydus Lifesciences

This global pharmaceutical company is headquartered in India and manages the commercial distribution of various health products.

MSN Laboratories

Based in India, this manufacturer specializes in developing active pharmaceutical ingredients and finished dosage forms for global markets.

Bayer

This multinational pharmaceutical and life sciences company is the original manufacturer of the brand-name drug Adempas.

The details

MSN Laboratories handled the manufacturing of the generic drug, while Zydus Lifesciences is managing the commercial launch across the United States. All five dosage strengths were released simultaneously to ensure widespread availability for patients.

Global Adempas sales reached $850 million in 2025.
Zydus Lifesciences shares closed on the NSE on October 5, 2026.

Healthcare
Sept. 30
Acrotech Biopharma Launched ADQUEY Ointment
Healthcare
Sept. 28
FDA Granted Tentative Approval for Lupin Apixaban
Heart Disease
Sept. 28
FDA Approved Label Update for PAH Drug Sotatercept

Market Landscape

The introduction of generic riociguat follows the standard trajectory of the FDA's generic drug approval process to increase market competition. This move allows the companies to capture market share from the existing brand-name holder.

Patients may see reduced costs for long-term treatment of pulmonary hypertension due to the introduction of lower-priced generic alternatives. Shoppers and healthcare providers should check local pharmacy availability to confirm stock of the new dosage options.

The takeaway

The availability of generic riociguat provides patients with necessary medication at potentially lower price points than the brand-name equivalent. Consumers should consult their physicians to determine if transitioning to a generic version is appropriate for their specific treatment plan.